Document Detail


Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
MedLine Citation:
PMID:  20393936     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Indomethacin is used as standard therapy to close a patent ductus arteriosus (PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo-oxygenase inhibitor, may be as effective as indomethacin with fewer side effects.
OBJECTIVES: To determine the effectiveness and safety of ibuprofen compared to placebo or no intervention for closing a PDA in preterm and/or low birth weight infants. To determine the effectiveness and safety of ibuprofen compared to other cyclo-oxygenase inhibitors for closing a PDA in preterm and/or low birth weight infants.
SEARCH STRATEGY: MEDLINE, EMBASE, The Cochrane Library, the reference lists of identified studies, meta-analyses and personal files were searched in December 2009.
SELECTION CRITERIA: Randomized or quasi-randomized controlled trials of ibuprofen for the treatment of a PDA in newborn infants.
DATA COLLECTION AND ANALYSIS: Data collection and analysis conformed to the methods of the Cochrane Neonatal Review Group.
MAIN RESULTS: Twenty studies are included in this review (6 studies added in this update). One study (n = 136) compared ibuprofen to placebo. Ibuprofen reduced the composite outcome of infant deaths, infants who dropped out or required rescue treatment [RR 0.58 (95% CI 0.38, 0.89); RD -0.22 (95% CI -0.38, -06); NNTB 5 (95% CI 3,17)]. Failure rates for PDA closure with ibuprofen compared to indomethacin was reported in 19 studies (n = 956 infants). There was no statistically significant difference between the groups [typical RR 0.94 (95% CI 0.76, 1.17)]; typical RD -0.02 (95% CI -0.07, 0.04); I(2) = 0%]. The risk of developing necrotizing enterocolitis (NEC) was reduced for ibuprofen [15 studies (n = 865); typical RR 0.68 (95% CI 0.47, 0.99); typical RD -0.04 (95% CI -0.08, -0.00; (p = 0.04); NNTB 25 (95% CI 13, infinity); I(2) = 0%]. There is less evidence of transient renal insufficiency in infants who receive ibuprofen compared to indomethacin. No other important differences were noted for common neonatal morbidities. Oro-gastric administration of ibuprofen appears as effective as i.v. administration.
AUTHORS' CONCLUSIONS: Ibuprofen is effective in closing a PDA. Ibuprofen is as effective as indomethacin in closing a PDA and reduces the risk of NEC and transient renal insufficiency. Given the reduction in NEC noted in this update, ibuprofen currently appears to be the drug of choice. Studies are needed to evaluate the effect of ibuprofen compared to indomethacin treatment on longer term outcomes in infants with PDA.
Authors:
Arne Ohlsson; Rajneesh Walia; Sachin S Shah
Related Documents :
11054226 - Defining the role of extended saphenofemoral junction ligation: a prospective comparati...
9377136 - Ultrasonographic study of ductus venosus in healthy neonates.
8410386 - Indomethacin and recurrent ileal perforations in a preterm infant.
2804176 - Pulsed doppler measurement of left ventricular output as early predictor of symptomatic...
7097666 - Offspring of teenage mothers: congenital malformations, low birth weights and other fin...
15371566 - Serum adiponectin concentrations in newborn infants in early postnatal life.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2010-04-14
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-05-21     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD003481     Citation Subset:  IM    
Affiliation:
Departments of Paediatrics, Obstetrics and Gynaecology and Health Policy, Management and Evaluation, University of Toronto, 600 University Avenue, Toronto, Ontario, Canada, M5G 1X5.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cyclooxygenase Inhibitors / adverse effects,  therapeutic use*
Ductus Arteriosus, Patent / drug therapy*
Humans
Ibuprofen / adverse effects,  therapeutic use*
Indomethacin / adverse effects,  therapeutic use
Infant, Low Birth Weight*
Infant, Newborn
Infant, Premature*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 15687-27-1/Ibuprofen; 53-86-1/Indomethacin
Comments/Corrections
Update In:
Cochrane Database Syst Rev. 2013;4:CD003481   [PMID:  23633310 ]
Update Of:
Cochrane Database Syst Rev. 2008;(1):CD003481   [PMID:  18254020 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exercise based rehabilitation for heart failure.
Next Document:  Self-monitoring and self-management of oral anticoagulation.